â– LECTURE OVERVIEW: Diabetic Retinopathy is a microvascular complication of chronic diabetes, classified into Non-Proliferative (NPDR) and Proliferative (PDR) phases.
â– PATHOPHYSIOLOGIC MECHANISMS:
1. Sorbitol Depletion: Chronic hyperglycemia drives intracellular aldose reductase to convert glucose to sorbitol. Sorbitol accumulation causes osmotic stress, selectively destroying pericytes.
2. Microaneurysms: Loss of supporting pericytes weakens capillary walls, leading to microaneurysms and leakage.
3. Systemic Retinal Ischemia: Progressive capillary closures cause retinal ischemia.
4. VEGF Surge: Ischemic retinocytes synthesize and secrete high-yield levels of Vascular Endothelial Growth Factor (VEGF).
5. Neovascularization: Excess VEGF drives neovascularization—the growth of fragile, abnormal new blood vessels over the optic disc and retina.
6. Hemorrhage and Traction: These fragile vessels are prone to rupture, leading to vitreous hemorrhage and subsequent fibrous scarring that can cause tractional retinal detachment.
â– TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
â– SECONDARY PREVENTION METRICS:
Implementing long-term dietary adaptations, physical therapy, and compliance aids reduces the rate of recurring acute crises by more than half.
[HY-BOARD-1239]
🌟 Dynamic Clinical Key:
To prevent blindness, patients with proliferative diabetic retinopathy are treated with intravitreal anti-VEGF monoclonal antibodies (e.g., Bevacizumab, Ranibizumab) and pan-retinal photocoagulation (PRP) to ablate outer ischemic areas and reduce VEGF release. Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Patient education regarding warning signs and therapy adherence is the cornerstone of secondary prevention.